Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 253

The DOI matches its Crossref record.

Abstract A25: Public and provider awareness and use of a CA-125 test for ovarian cancer

Stewart, Sherri L., Rim, Sun Hee, Gelb, Cynthia A.·2010·Cancer Prevention Research

Abstract

Introduction: CA-125 is a serum marker approved for detecting recurrent ovarian cancer in women with a personal history of ovarian cancer. Several large trials have investigated the use of CA-125 (alone or in combination with transvaginal ultrasound [TVU]) as a screening test for ovarian cancer. However, this test has generally been associated with a low positive predictive value and trials have concluded that screening asymptomatic women in the average risk population with CA-125 is not beneficial. Still, there remains widespread discussion and marketing of ovarian cancer screening tests that include CA-125. Since little is known about public and provider awareness of CA-125, the objective of this study was to measure women's familiarity with the CA-125 test, and clinician beliefs about the effectiveness of screening for ovarian cancer with CA-125 in the United States. Methods: In 2008, CDC funded the collection of data as part of its national awareness campaign, Inside Knowledge: Get the Facts About Gynecologic Cancer. Several questions related to CA-125 were included as part of a standardized, survey administered annually in the contiguous United States by Porter Novelli. The HealthStyles survey included 2,991 female respondents age ≥ 18 years, and the DocStyles survey included 1,250 physician respondents of family/general practitioners (n=510), internists (n=490), and obstetrician/gynecologists (n=250). Participant responses to CA-125-related questions for the HealthStyles survey were weighted to match the demographic distribution of the general population. Chi-square tests were used to assess differences with the p-value set to 0.05. Results: Overall, most women (56%) had not heard of the CA-125 test, 29% had heard of it, and 15% were unsure. Demographic characteristics generally were similar for women who had not heard of the CA-125 test, except that women who had heard of the test more often were over age 45 (58% vs 37%) (p<0.0001) and were peri- or post-menopausal (54% vs 35%) (p<0.0001), compared to women who had not heard of CA-125. Few women (12%) had ever had a CA-125 test. About 15% of women who reported being “very concerned” about getting ovarian cancer also reported having had a CA-125 test. In the DocStyles results, the majority (53%) of physicians said that both CA-125 and TVU are effective screening tests for ovarian cancer. A greater proportion of OB/GYNs (57%) reported neither CA125 nor TVU were effective as screening tests for asymptomatic women in the average risk population than family/general practitioners (34%) or internists (30%) (p<0.0001). Conclusions: The large percentage of physicians who believe CA-125 is an effective screen for ovarian cancer signals the need for improved education. Educational efforts geared toward the public and providers that include both lack of evidence for screening with CA-125, as well as the potential harms of false-positive CA-125 tests should be a priority for public health programs and awareness campaigns. Citation Information: Cancer Prev Res 2010;3(1 Suppl):A25.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1940-6207.prev-09-a25

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Metadata

Authors
Stewart, S. L., Rim, S. H., & Gelb, C. A.
Venue
Cancer Prevention Research
Published
2010-01
Volume
3
Issue
1_Supplement
Pages
A25-A25
ISSN
  • 1940-6207 (ISSN-L)
  • 1940-6215
OpenAlex
W2318161371
Cited by
253
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abstract A25: Public and provider awareness and use of a CA-125 test for ovarian cancer. https://app.cochat.ai/papers/10.1158/1940-6207.prev-09-a25
The paper
Stewart, S. L., Rim, S. H., & Gelb, C. A. (2010). Abstract A25: Public and provider awareness and use of a CA-125 test for ovarian cancer. Cancer Prevention Research. https://doi.org/10.1158/1940-6207.prev-09-a25

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.